Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer
The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with prostate cancer, when administered as two injections twelve weeks apart.
Prostatic Neoplasms
DRUG: Leuprolide Mesylate
Efficacy of Leuprolide Mesylate (LMIS 25mg), The percentage of subjects with a serum testosterone concentration suppressed to castrate levels (â‰¤ 50 ng/dL) from Day 28 through Day 168., 168 days
Number of Participants With Adverse Events, Determining the safety and tolerability of LMIS 25 mg based on adverse events (AEs)., 168 days
This is a multi-national, multi-center, open-label, single-arm study. All subjects will be males with prostate cancer judged to be candidates for medical androgen ablation therapy and all will receive two injections of LMIS 25 mg twelve-week apart in an unblinded fashion.